Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)
Barbell Medicine Podcast
Barbell Medicine
4.8 • 1.3K Ratings
🗓️ 24 March 2026
⏱️ 31 minutes
🧾️ Download transcript
Summary
In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training.
Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/
Timestamps:
0:00 — Introduction
3:26 — VO2 Max vs. Cardiorespiratory Fitness for Longevity
14:11 — GLP-1 Costs: What you should actually be paying now
21:43 — Is Walking Enough for Cardiovascular Health?
Next Steps:
For evidence-based resistance training programs: barbellmedicine.com/training-programs
For individualized training consultation: barbellmedicine.com/coaching
Explore our full library of articles on health and performance: barbellmedicine.com/resources
To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
Resources:
- JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428
- JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243
- Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/
- Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepbound
- NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.html
- Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipron
Our Sponsors:
* Check out Chilipad and use my code sleep.me/BBM for a great deal: https://sleep.me
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor and use my code factormeals.com/bbm50off for a great deal: https://www.factor75.com
* Check out Quince and use my code quince.com/bbm for a great deal: https://www.quince.com
Advertising Inquiries: https://redcircle.com/brands
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome back to the Barbaugh Medicine Direct Line, our monthly Ask Us Anything for our Barbell Medicine Plus subscribers. I'm Dr. Jordan Flagenbaum. We've got a stacked set of questions today and a lot of it comes down to one recurring theme. The advice that was supposed to protect you might be doing the opposite. And to help me unpack all of this, we have the second most hands on, I'm Dr. North America. Dr. Austin Baraki, what's going on, dude? Hey, doing all right. I'm looking forward to |
| 0:38.1 | the breadth of topics that you've pulled together or that our audiences pulled together. I just |
| 0:42.6 | wrapped up some training this morning and I'm comfortable, ready to go. All right, let's get into |
| 0:47.4 | the first question. This one's on V-O-2 Max versus cardiorethreatpiratory fitness for longevity. |
| 0:52.3 | The question is, is V-O-2 Max the metric we should or could reference for cardiorespiratory fitness for longevity. The question is, is V-O-2 Max the metric we should |
| 0:55.5 | or could reference for cardiorespiratory fitness when it comes to longevity? Dr. Eric Topol |
| 1:00.5 | points out the data comes mostly from measures of cardiorespiratory fitness, not actual measures |
| 1:04.9 | of VOTU-Mex. How does this square with Dr. Peter Atia's recommendations for VO2 Max? |
| 1:32.5 | So to start, yeah, these aren't the same things. VO2 Max and Cardi Restopority Fitness are distinctly different. And most of the longevity studies that Dr. Atia has cited, they don't actually ever measure VO2 Max. We can fully concede that. VO2 Max, for those who are listening to Home and may be unfamiliar with what it actually is, it's a measurement of your maximum oxygen uptake. It usually requires a maximal effort test with a metabolic cart to get a real number. Cardiorespiratory fitness, on the other hand, is more |
| 1:37.6 | broad than that. In most large studies, it's an estimated treadmill test, estimated exercise test |
| 1:43.9 | sort of thing. |
| 1:44.6 | You take it to tolerance where people either have signs, if it's like a cardiac rehab sort of situation or just otherwise they feel some breathlessness, they can't continue. |
| 1:54.3 | And so you get a measurement of metabolic equivalence at peak effort. |
| 1:58.1 | You can also get a submaximal test. |
| 1:59.9 | There's also questionnaires. |
| 2:00.7 | There's a bunch |
| 2:01.2 | of different ways to test it. But most of the time in the research, it's an exercise tolerance test |
| 2:05.6 | sort of thing. So Atia, despite this, gives specific VO2 max percentile targets by age and sex |
| 2:12.6 | in his book, despite the underlying studies, not actually measuring that. So he says, despite all this, that VOTU Max is the single most powerful marker for longevity. |
| 2:23.9 | He's been saying it on his podcast. |
| 2:25.2 | It's all over his book, Outlive. |
| 2:27.2 | And honestly, he's probably right directionally. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Barbell Medicine, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Barbell Medicine and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.
